JACC. Case reports · 2026
Unmasking Essential Thrombocythemia in Heparin-Induced Thrombocytopenia After Coronary Artery Bypass Grafting.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kumari Sapna, Thapa Basanta, Roomi Sohaib, Sabados Alison, Okoev Grigori, Konda Prasad, Tolerico Paul, Patel Nishi, Chaudhary Omair, Shah Vishal N
Аннотация
BACKGROUND: Heparin-induced thrombocytopenia (HIT) and JAK2 V617F-positive essential thrombocythemia (ET) are prothrombotic conditions that complicate postoperative management.
CASE SUMMARY: A 68-year-old man underwent coronary artery bypass grafting (CABG) and developed recurrent arterial thrombosis with an abrupt platelet decline prompting evaluation for HIT. Platelet factor 4/heparin immunoassays were positive, whereas serotonin release assays remained negative during potent P2Y12 receptor inhibition. Despite discordant laboratory results, a probable diagnosis of HIT was made. In addition to fulfilling other diagnostic criteria, genetic testing revealed a JAK2 V617F mutation, confirming the diagnosis of ET.
DISCUSSION: Unexplained persistent thrombocytosis in the setting of prior arterial thrombosis should raise suspicion for an underlying myeloproliferative neoplasm. Moreover, the coexistence of JAK2 V617F-positive ET and probable HIT following CABG confers a heightened thrombotic risk and underscores the diagnostic challenges associated with functional HIT assays in the context of potent P2Y12 receptor inhibition.
TAKE-HOME MESSAGE: Persistent unexplained thrombocytosis with prior arterial thrombosis should raise suspicion for an occult myeloproliferative neoplasm, whereas postoperative HIT remains a clinical consideration despite negative functional assays, particularly in the context of potent P2Y12 receptor inhibition.
CASE SUMMARY: A 68-year-old man underwent coronary artery bypass grafting (CABG) and developed recurrent arterial thrombosis with an abrupt platelet decline prompting evaluation for HIT. Platelet factor 4/heparin immunoassays were positive, whereas serotonin release assays remained negative during potent P2Y12 receptor inhibition. Despite discordant laboratory results, a probable diagnosis of HIT was made. In addition to fulfilling other diagnostic criteria, genetic testing revealed a JAK2 V617F mutation, confirming the diagnosis of ET.
DISCUSSION: Unexplained persistent thrombocytosis in the setting of prior arterial thrombosis should raise suspicion for an underlying myeloproliferative neoplasm. Moreover, the coexistence of JAK2 V617F-positive ET and probable HIT following CABG confers a heightened thrombotic risk and underscores the diagnostic challenges associated with functional HIT assays in the context of potent P2Y12 receptor inhibition.
TAKE-HOME MESSAGE: Persistent unexplained thrombocytosis with prior arterial thrombosis should raise suspicion for an occult myeloproliferative neoplasm, whereas postoperative HIT remains a clinical consideration despite negative functional assays, particularly in the context of potent P2Y12 receptor inhibition.